This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (683) Immunology, Allergy, Rheumatology (140) Infectious Diseases (non-STD/STI) (1726) Prevention and Health Promotion (1362) Chronic Conditions (434)

Published on in Vol 14 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/72549, first published .
Optimization of Preemptive Therapy for Cytomegalovirus Infections With Valganciclovir Based on Therapeutic Drug Monitoring: Protocol for a Phase II, Single-Center, Single-Arm Trial

Optimization of Preemptive Therapy for Cytomegalovirus Infections With Valganciclovir Based on Therapeutic Drug Monitoring: Protocol for a Phase II, Single-Center, Single-Arm Trial

Optimization of Preemptive Therapy for Cytomegalovirus Infections With Valganciclovir Based on Therapeutic Drug Monitoring: Protocol for a Phase II, Single-Center, Single-Arm Trial

Authors of this article:

Naoki Tamura1, 2 Author Orcid Image ;   Kotaro Itohara1 Author Orcid Image ;   Yo Ueda3 Author Orcid Image ;   Yumi Kitahiro1 Author Orcid Image ;   Kazuhiro Yamamoto1, 4 Author Orcid Image ;   Tomohiro Omura1 Author Orcid Image ;   Toshiyasu Sakane2 Author Orcid Image ;   Jun Saegusa3 Author Orcid Image ;   Ikuko Yano1 Author Orcid Image
Article Authors Cited by Tweetations Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.